Episode 45: Revisiting COVID-19 – Variants and Vaccines

Episode 45: Revisiting COVID-19 – Variants and Vaccines

Chadi is rejoined by Priya Sampathkumar, MD, infectious disease specialist and hospital epidemiologist, Mayo Clinic, to provide a state of affairs for the current COVID-19 situation in America, including why the country has failed to get more of its people vaccinated, why myocarditis has been a frequent side effect in some people, why the delta variant and other future variants come about, whether booster shots should be administered to healthy individuals and those who have had COVID-19 in the past, how safe it is for kids to return to in-person school and more of the important talking points surrounding the virus at this time.

Related Resources

N/A

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More